Johnson Matthey : Factsheet

Sales (excluding pm) -

£3,922m

New Markets

Health9%

6%

Efficient
Natural		Clean Air
Resources
	59%
	26%
Chart excludes eliminations
		Clean Air
Heavy	HDD Asia	Other
Duty	HDD	8%	1%
	LDV Europe
Diesel
Europe
(HDD)	10%		38%
31%
			Light Duty
HDD Americas		Vehicles
	13%		(LDV)
LDV Americas		68%
	LDV Asia
	11%
			19%

• A global leader providing catalysts to reduce harmful emissions from vehicles
• Light Duty Vehicles - catalysts for cars and other light duty vehicles powered by all fuel types
• Heavy Duty Diesel - catalyst systems for diesel powered trucks and buses and non road machinery
• Other - catalyst systems for stationary equipment
• Margin: 11.2%
• Return on invested capital: 15.6%
• Employees: 6,289

Our strategy will deliver:

Medium term profit growth and sustained

cash generation to support

growth opportunities

Profit growth and

sustained cash generation

Underlying operating profit -

£504m

	Health	New Markets
	2%
	5%
Efficient
Natural		Clean Air
Resources
	47%
46%

Chart excludes corporate costs

Efficient Natural Resources

Advanced Glass	Diagnostic Services
Technologies	4%
6%

Catalyst Technologies 45%

PGM Services 45%

• Catalyst Technologies - manufactures speciality catalysts and additives, licenses process technology and delivers services to the chemical and oil & gas industry
• PGM Services - marketing, distribution, refining and recycling of platinum group metals (pgms), fabricates products using precious metals and related materials and manufactures pgm chemicals
• Advanced Glass Technologies - precious metal pastes and enamels primarily for the automotive industry
• Margin: 25.4%
• Return on invested capital: 25.2%
• Employees: 4,017

Our strategy will deliver:

Growth driven by decarbonisation

and circularity solutions

Medium term growth

Truly global group with increasing

emerging market exposure

Rest of World

Rest of Asia7%

12%

China	Europe
13%	41%

North America 27%

Health

Innovators 38%

Generics 62%

• Develops and manufactures active pharmaceutical ingredients (APIs) for a variety of treatments
• Operates in the large and growing outsourced small molecule API market
• Providing solutions to the complex problems of both generic and innovator companies
• Margin: 13.1%
• Return on invested capital: 6.4%
• Employees: 958

Our strategy will deliver:

c.£100m additional operating profit from

our pipeline of APIs by 2025/26

Break out growth

Strong bottom line rewards for

shareholders

Underlying EPS			CAGR = 0.4%
(pence)
		209.1	208.4	228.8	199.2
178.7	182.0
2016	2017	2018	2019	2020	2021
Ordinary DPS			CAGR = -0.4%
(pence)
71.5	75.0	80.0	85.5	55.6	70.0
2016	2017	2018	2019	2020	2021

New Markets

Other

Life Science 5%

Technologies

15%

Medical Device Components

17%Alternative Powertrain 63%

• Alternative Powertrain - provides battery materials for automotive applications, battery systems for a range of applications and fuel cell technologies
• Medical Device Components - leverages our science and technology to develop products found in devices used in medical procedures
• Life Science Technologies - provides advanced catalysts and processes to the pharmaceutical and agricultural chemicals markets
• Margin: 2.5%
• Return on invested capital: 3.4%
• Employees: 2,132

Our strategy will deliver: Break out growth driven by exciting, high growth opportunities

Break out growth

All numbers based on full year 2020/21. All charts show figures for sales unless otherwise noted.

Cautionary statement: This factsheet contains forward looking statements that are subject to risk factors associated with, amongst other things, the economic and business circumstances occurring from time to time in the countries and sectors in which Johnson Matthey operates. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a wide range of variables which could cause actual results to differ materially from those currently anticipated.